10-K: Paysign Inc. Reports 24.3% Revenue Increase in 2023 Driven by Plasma and Pharma Growth

Sentiment:

Annual Results 27 March 2024 7:46 AM

Paysign Inc. saw a significant 24.3% increase in revenue in 2023, primarily driven by growth in its plasma and pharmaceutical sectors.

Capital raiseThe company evaluates raising capital to enable diversification into new market verticals.The company believes it can support existing business and expand into new markets using internally generated funds if it does not raise new capital.

Better than expectedThe company's revenue growth of 24.3% significantly exceeded expectations.The company's net income of $6.46 million was a substantial improvement over the previous year.The company's total revenue conversion rate increased to 2.77% of gross dollar volume loaded on cards.

Summary

Paysign, Inc., a provider of prepaid card solutions, reported a 24.3% increase in total revenue for the year ended December 31, 2023, reaching $47.27 million compared to $38.03 million in 2022.
The company's revenue growth was primarily fueled by a 20.8% increase in plasma industry revenue, a 34.7% increase in pharma industry revenue, and a substantial 340.1% increase in other revenue streams.
The company manages approximately 600 card programs with approximately 6.4 million participating cardholders as of December 31, 2023.
Gross profit increased by 15.2% to $24.14 million, while operating expenses rose by 17.9% to $24.30 million.
Paysign reported a net income of $6.46 million for 2023, a significant improvement compared to $1.03 million in 2022, primarily due to a release of a valuation allowance on deferred tax assets.
The company's gross dollar volume loaded on cards was $1.706 billion in 2023, compared to $1.595 billion in 2022.
The company's total revenue conversion rate was 2.77% of gross dollar volume loaded on cards in 2023, compared to 2.38% in 2022.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and improved profitability. However, there are some concerns about increasing operating expenses and ongoing legal proceedings, which temper the overall sentiment.

Positives

The company experienced significant revenue growth across all sectors, particularly in plasma and pharma.
The company's net income saw a substantial increase due to a release of a valuation allowance on deferred tax assets.
The company's gross dollar volume loaded on cards increased, indicating strong usage of its prepaid card programs.
The company's total revenue conversion rate improved, indicating better monetization of card loads.
The company added 20 net new Plasma programs, launched 24 net new Pharma programs, and added 1 net new Other prepaid program.

Negatives

Operating expenses increased by 17.9%, outpacing the growth in gross profit.
The company recorded a loss from operations of $167,255, a decline of $511,590 compared to income from operations of $344,335 during the same period last year.
The company's gross margin decreased from 55.1% to 51.1% due to increased costs.
Selling, general, and administrative expenses increased due to higher compensation, stock-based compensation, and technology costs.

Risks

The company operates in a highly regulated environment, and failure to comply with laws and regulations could negatively impact the business.
A data security breach could expose the company to liability and costly litigation.
The company relies on relationships with card-issuing banks, and the loss of these relationships could adversely affect the business.
The company faces intense competition in the financial services and healthcare industries.
The company's stock price is volatile and could be subject to wide fluctuations.
The company is subject to legal proceedings, including securities class action and derivative lawsuits, which could result in significant costs and management distraction.

Future Outlook

The company plans to continue investing in technology improvements, sales and marketing, fraud prevention, customer service, and regulatory compliance in 2024. They also evaluate raising capital to diversify into new market verticals, but believe they can support existing business and expand into new markets using internally generated funds.

Industry Context

The prepaid card market continues to experience significant growth due to consumers, corporations, and governments embracing improved technology, greater convenience, and more product choices. Paysign is positioned to capitalize on this trend with its vertically integrated platform and diverse product offerings.

Comparison to Industry Standards

The document references Javelin Advisory Services' forecast of 8% annual growth in the open-loop prepaid card market from 2024 through 2027, with total open-loop loads projected to reach $836 billion by 2027. Paysign's 24.3% revenue growth in 2023 significantly exceeds this industry forecast, indicating strong performance relative to the broader market.
The document mentions that Paysign services approximately 39% of the plasma collection centers in the United States. This indicates a strong market position within the plasma donation sector.
The document notes that the prepaid card market is divided into consumer-funded, corporate-funded, and government-funded programs. Paysign's product offerings span all three categories, suggesting a diversified approach compared to competitors focused on a single segment.

Legal Proceedings

The company is involved in a securities class action lawsuit, which has a proposed settlement of $3,750,000, fully covered by the company's directors-and-officers insurance policy.
The company is also named as a nominal defendant in four stockholder derivative actions, which are currently pending in the United States District Court for the District of Nevada.

Related Party Transactions

A former member of the Board is a partner in a law firm that the Company engages for services. During the year ended December 31, 2022, the Company incurred legal expenses of $126,628 with the related party law firm. There were no related party expenses in 2023.

Stakeholder Impact

Shareholders will benefit from the company's strong revenue growth and improved profitability.
Employees may benefit from continued hiring and investment in the company's growth.
Customers will benefit from the company's continued investment in technology and customer service.
Suppliers and creditors will benefit from the company's improved financial position.

Next Steps

The company plans to continue investing in technology improvements, sales and marketing, fraud prevention, customer service, and regulatory compliance.
The company will evaluate raising capital to enable diversification into new market verticals.

Key Dates

Date	Description
1995-08-24	Paysign, Inc. was incorporated.
2011	Paysign began marketing a corporate incentive prepaid card-based payment solution targeting the plasma donation industry.
2019	The company began marketing its DDA Debit Card, branded Paysign Premier Digital Bank Account, in the third quarter.
2020-03-19	Yilan Shi v. Paysign, Inc. et al., a securities class action complaint, was filed.
2020-03-25	Lorna Chase v. Paysign, Inc. et al., a securities class action complaint, was filed.
2020-04-02	Smith & Duvall v. Paysign, Inc. et al., a securities class action complaint, was filed.
2020-05-21	Smith & Duvall v. Paysign, Inc. et al. was voluntarily dismissed.
2020-09-17	Andrzej Toczek, derivatively on behalf of Paysign, Inc. v. Mark R. Newcomer, et al., a stockholder derivative action, was filed.
2022-05-09	John K. Gray, derivatively on behalf of Paysign, Inc. v. Mark Attinger, et al., a stockholder derivative action, was filed.
2023-03-21	The Board authorized a stock repurchase program to repurchase up to $5 million of common stock.
2023-10-02	Simone Blanchette, derivatively on behalf of Paysign, Inc. v. Mark Newcomer, et al., a stockholder derivative action, was filed in state court.
2023-10-10	The Simone Blanchette derivative action was removed to federal district court.
2023-12-15	The parties agreed in principle to a proposed settlement of the Securities Class Action.
2023-12-27	Mo Jeewa, derivatively on behalf of Paysign, Inc. v. Mark R. Newcomer, et al., a stockholder derivative action, was filed.
2024-01-04	The Court preliminarily approved a settlement in the amount of $3,750,000 for the Securities Class Action.
2024-03-22	The latest practicable date for share information.
2024-04-17	The final approval hearing for the Securities Class Action settlement is scheduled.

Keywords

prepaid cards, payment processing, plasma, pharmaceutical, corporate incentives, patient affordability, financial services, fintech, revenue growth, card programs

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.